04:37 AM EDT, 09/10/2025 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said late Tuesday it priced a public offering of its securities for about $251 million in expected gross proceeds, upsized from a previously planned $150 million.

The offering consists of about 6.5 million common shares at $33 apiece and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1.1 million shares.

Underwriters have a 30-day overallotment option to acquire up to 1.1 million additional shares.

The company expects the offering to close Thursday and plans to use the net proceeds to advance its preclinical and clinical development activities, among other things.